Transperineal template prostate‐mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer
Open Access
- 30 August 2015
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 118 (3) , 384-390
Abstract
Objectives: To determine whether modified transperineal template prostate‐mapping ( TTPM ) biopsy protocols, altering the template or the biopsy density, have sensitivity and negative predictive value ( NPV ) equal to full 5‐mm TTPM . Patients and Methods: Retrospective analysis of an institutional registry including treatment‐naïve men undergoing 5‐mm TTPM biopsy analysed in a 20‐zone fashion. The value of three modified strategies was assessed by comparing the information provided by selected zones against full 5‐mm TTPM . Strategy 1, did not consider the findings of anterior areas; strategies 2 and 3 simulated a reduced biopsy density by excluding intervening zones. A bootstrapping technique was used to calculate reliable estimates of sensitivity and NPV of these three strategies for the detection of clinically significant disease (maximum cancer core length ≥4 mm and/or Gleason score ≥3 + 4). Results: In all, 391 men with a median (interquartile range, IQR ) age of 62 (58–67) years were included. The median ( IQR ) PSA level and PSA density were 6.9 (4.8–10) ng/mL and 0.17 ( IQR 0.12–0.25) ng/mL/mL, respectively. A median ( IQR ) of 6 (2–9) cores out of 48 (33–63) taken per man were positive for prostate cancer. No cancer was detected in 67 men (17%), whilst low‐, intermediate‐ and high‐risk disease was identified in 78 (20%), 80 (21%), and 166 (42%), respectively. Strategy 1, 2 and 3 had sensitivities of 78% [95% confidence interval ( CI ) 73–84%], 85% (95% CI 80–90%) and 84% (95% CI 79–89%), respectively. The NPV s of the three strategies were 73% (95% CI 67–80%), 80% (95% CI 74–86%) and 79% (95% CI 72–84%), respectively. Conclusion: Altering the template or decreasing sampling density has a substantial negative impact on the ability of TTPM biopsy to exclude clinically significant disease. This should be considered when modified TTPM biopsy strategies are used to select men for tissue‐preserving approaches, and when modified TTPM are used to validate new diagnostic tests.Keywords
Funding Information
- Prostate Cancer UK
- Wellcome Trust
- Siemens
- GE Healthcare
- GlaxoSmithKline
- GE Healthcare
This publication has 25 references indexed in Scilit:
- Transrectal Saturation Technique May Improve Cancer Detection as an Initial Prostate Biopsy Strategy in Men with Prostate-specific Antigen <10 ng/mlEuropean Urology, 2014
- Critical Evaluation of Magnetic Resonance Imaging Targeted, Transrectal Ultrasound Guided Transperineal Fusion Biopsy for Detection of Prostate CancerJournal of Urology, 2013
- Transperineal Magnetic Resonance Image Targeted Prostate Biopsy Versus Transperineal Template Prostate Biopsy in the Detection of Clinically Significant Prostate CancerJournal of Urology, 2013
- Contemporary Role of Systematic Prostate Biopsies: Indications, Techniques, and Implications for Patient CareEuropean Urology, 2013
- Accuracy of Primary Systematic Template Guided Transperineal Biopsy of the Prostate for Locating Prostate Cancer: A Comparison With Radical Prostatectomy SpecimensJournal of Urology, 2012
- Characterizing Clinically Significant Prostate Cancer Using Template Prostate Mapping BiopsyJournal of Urology, 2011
- Three-Dimensional Prostate Mapping Biopsy Has a Potentially Significant Impact on Prostate Cancer ManagementJournal of Clinical Oncology, 2009
- Three‐dimensional 26‐core biopsy‐based patient selection criteria for nerve‐sparing radical prostatectomyInternational Journal of Urology, 2008
- Appropriate Patient Selection in the Focal Treatment of Prostate Cancer: The Role of Transperineal 3-Dimensional Pathologic Mapping of the Prostate—A 4-Year ExperienceUrology, 2007
- Clinical staging of prostate cancer: a computer‐simulated study of transperineal prostate biopsyBJU International, 2005